Holen Sie sich die Stockscreener-App
4.95
1.64%
0.08
Handel nachbörslich:
4.95
Schlusskurs vom Vortag:
$4.87
Offen:
$4.87
24-Stunden-Volumen:
171.83K
Relative Volume:
1.40
Marktkapitalisierung:
$255.30M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-2.1154
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
+1.02%
1M Leistung:
+18.71%
6M Leistung:
+7.84%
1J Leistung:
-9.01%
1-Tages-Spanne:
$4.845
$5.10
1-Wochen-Bereich:
$4.62
$5.19
52-Wochen-Spanne:
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie FHTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.95 | 255.30M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks
Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World
BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com
Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World
Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire
10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World
(FHTX) Trading Report - news.stocktradersdaily.com
Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World
JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN
FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus
FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus
Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire
Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView
FHTX Exceeds Revenue Expectations and Advances Pipeline Programs | FHTX Stock News - GuruFocus
Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks
Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World
Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan
Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
(FHTX) Trading Advice - news.stocktradersdaily.com
Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World
JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India
Foghorn Therapeutics expands board with biotech veterans - Investing.com
Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus
Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Foghorn Therapeutics Inc-Aktie (FHTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Costa Carlos | Chief People Officer |
Sep 23 '24 |
Option Exercise |
3.72 |
857 |
3,188 |
857 |
| Costa Carlos | Chief People Officer |
Sep 20 '24 |
Sale |
10.04 |
35,756 |
358,990 |
0 |
| Costa Carlos | Chief People Officer |
Sep 23 '24 |
Sale |
10.17 |
857 |
8,716 |
0 |
| Costa Carlos | Chief People Officer |
Sep 18 '24 |
Option Exercise |
3.72 |
11,574 |
43,055 |
11,574 |
| Costa Carlos | Chief People Officer |
Sep 18 '24 |
Sale |
10.05 |
11,574 |
116,319 |
0 |
| Costa Carlos | Chief People Officer |
Sep 17 '24 |
Option Exercise |
3.72 |
10,272 |
38,212 |
10,272 |
| Costa Carlos | Chief People Officer |
Sep 16 '24 |
Option Exercise |
3.72 |
400 |
1,488 |
400 |
| Costa Carlos | Chief People Officer |
Sep 17 '24 |
Sale |
10.04 |
10,272 |
103,131 |
0 |
| Costa Carlos | Chief People Officer |
Sep 16 '24 |
Sale |
10.00 |
400 |
4,000 |
0 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):